Nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients: a potential biomarker with diagnostic and prognostic utility

dc.contributor.authorAydın, Mehmet Akif
dc.contributor.authorGül, G.
dc.contributor.authorKızıltan, R.
dc.contributor.authorAlgül, S.
dc.contributor.authorKemik, Özgür
dc.date.accessioned2021-05-15T11:33:59Z
dc.date.available2021-05-15T11:33:59Z
dc.date.issued2020
dc.departmentTıp Fakültesi Genel Cerrahi Anabilim Dalıen_US
dc.description.abstractOBJECTIVE: To evaluate the diagnostic and prognostic utility of nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients. PATIENTS AND METHODS: A total of 95 patients with colon cancer [mean (SD) age: 61.0 (1.7) years, 58.9% were males] and 50 healthy individuals [mean (SD) age: 61.0 (2.3) years. 52.0% were males] were included in this prospective multicenter study. Data on patient demographics (age, gender) and serum NAP1L1 levels were recorded in both control and colon cancer groups. In colon cancer patients. serum NAP1L1 levels were further analyzed with respect to TNM stages and tumor size. RESULTS: Serum NAP1L1 levels were significantly higher in colon cancer patients as compared with control subjects [median (min-max) 14(12-16) vs. 2(1-2) ng/mL, p<0.001]. In colon cancer patients, serum NAP1L1 levels were significantly higher for tumor size of >4 cm vs. <4 cm [15(12-16) vs. 12(12-14) ng/mL), p<0.001] and for M1 vs. MO stage [15(12-16) vs. 12(12-14) ng/mL), p<0.001]. Serum NAP1L1 levels were significantly higher in T4 stage tumors vs. T1, T2 and T3 stage tumors (p<0.001 for each), in T3 stage tumors vs. T1 and T2 stage tumors (p<0.001 for each) and in N2 stage tumors vs. N0 and N1 stage tumors (p<0.001 for each). CONCLUSIONS: Our findings revealed for the first time the substantial rise in serum NAP1L1 levels among colon cancer patients as compared to controls and as correlated with the disease progression. Accordingly. NAP1L1 seems to be a potential biomarker for colon cancer, offering clinically important information on early diagnosis and risk stratification.en_US
dc.identifier.doi10.26355/eurrev_202010_23403
dc.identifier.endpage10517en_US
dc.identifier.issn1128-3602
dc.identifier.issue20en_US
dc.identifier.pmid33155206
dc.identifier.scopus2-s2.0-85095760447
dc.identifier.scopusqualityQ2
dc.identifier.startpage10512en_US
dc.identifier.urihttps://doi.org/10.26355/eurrev_202010_23403
dc.identifier.urihttps://hdl.handle.net/20.500.12939/261
dc.identifier.volume24en_US
dc.identifier.wosWOS:000585086700033
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAydın, Mehmet Akif
dc.language.isoen
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColon Canceren_US
dc.subjectNAP1L1en_US
dc.subjectMarkeren_US
dc.subjectEarly Diagnosisen_US
dc.subjectRisk Stratificationen_US
dc.subjectStageen_US
dc.subjectControlsen_US
dc.titleNucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients: a potential biomarker with diagnostic and prognostic utility
dc.typeArticle

Dosyalar